ImmuPharma plc (LON:IMM – Get Free Report)’s share price rose 13.4% on Thursday . The stock traded as high as GBX 10.80 and last traded at GBX 10.50. Approximately 7,242,426 shares were traded during trading, a decline of 10% from the average daily volume of 8,073,004 shares. The stock had previously closed at GBX 9.26.
ImmuPharma Trading Down 4.7%
The firm’s 50 day moving average price is GBX 11.29 and its two-hundred day moving average price is GBX 5.56. The company has a market capitalization of £51.28 million, a price-to-earnings ratio of -11.46 and a beta of 1.53.
ImmuPharma Company Profile
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
Further Reading
- Five stocks we like better than ImmuPharma
- Overbought Stocks Explained: Should You Trade Them?
- 3 Under-the-Radar AI Stocks to Buy on the Dip
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- Your Thanksgiving Playbook: 3 Stocks Set to Benefit From Football Fever
- What Are Dividend Contenders? Investing in Dividend Contenders
- MarketBeat Week in Review – 11/10 – 11/14
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
